“I have followed the progress Addex has made in the field of allosteric modulation since inception and have been impressed by the discoveries they have made", said Dr. Schoepp. “I am delighted to join the team and very much look forward to bring my experience to help Addex advance its exciting portfolio and discovery platform."
Dr. Schoepp has published over 200 peer reviewed papers and is an inventor of 15 U.S. patents. His research has resulted in major contributions to the role of excitatory amino acid neurotransmitter glutamate in disease pathophysiology, pharmacology and therapeutics. Dr. Schoepp has been involved in the discovery of the first AMPA/kainate and metabotropic receptor negative and positive modulators for migraine, pain, cognition, anxiety disorders and schizophrenia. While at Lilly, he was a co-discoverer of the compound alivimopan (Entereg), a first in class peripherally restricted opioid antagonist for post-operative ileus.
At Merck, Dr. Schoepp and his team built a pipeline of innovative first in class agents for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia, including the first in class orexin receptor antagonist Suvorexant (Belsomra) for insomnia and the first in class oral CGRP antagonist ubrogepant (Ubrelvy) for migraine treatment. Dr. Schoepp earned his PhD in toxicology and pharmacology from the University of West Virginia.